Liver cirrhosis is the 10th most common cause of death in the western world. Infection is the most common precipitant of deterioration of liver function in cirrhosis. Endotoxin, derived from gram-negative organisms in the gut, can enter the circulation due to increased gut permeability and contributes to neutrophil dysfunction, infection risk and mortality in alcoholic cirrhotics. As probiotics decrease gram-negative organisms in the gut and/or decrease gut permeability, the investigators hypothesize that probiotic treatment would restore neutrophil function and prevent infection in alcoholic cirrhosis. The investigators hypothesize that administration of a probiotic mixture in patients with liver cirrhosis will improve innate immune function through alteration of the gut bacterial flora and gut barrier integrity. The aim of this randomised, double-blinded placebo-controlled study is to assess whether food supplementation with probiotic mixture improves neutrophil phagocytic capacity in patients with cirrhosis and decreases the incidence of significant infections. 92 patients with alcoholic cirrhosis will be included according to a sample size calculation from preliminary data. Patients will be randomized in two groups: Group 1 receives a probiotic mixture Group 2 receives a similar looking and tasting placebo without bacteria. The recruited patients will be treated for 6 months. Besides routine clinical and laboratory assessments, neutrophil function, toll-like receptor expression, endotoxin levels, bacterial DNA, cytokine levels, albumin oxidation, gut permeability and analysis of gut microflora will be performed. Furthermore nutritional status and quality of life will be assessed. Primary endpoints will be neutrophil phagocytosis. Secondary endpoints will be significant infection, neutrophil oxidative burst, neutrophil toll-like receptor expression, endotoxin levels, bacterial DNA; cytokine levels, albumin oxidation, gut barrier function and bacterial flora, nutritional status and quality of life. If our hypothesis holds true, probiotics will provide an easily applicable and cost effective method to improve immune function and to prevent infection in liver cirrhosis. It is possible that this can improve survival of patients with liver cirrhosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
92
6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
A similar looking and tasting powder with no active substances
Department of Internal Medicine, Medical University of Geraz
Graz, Austria
Change in neutrophil phagocytic capacity
Percentage of neutrophil granulocytes showing phagocytosis of FITC (fluorescein isothiocyanate) -labelled E.coli bacteria
Time frame: Change from baseline to 6 months
Number of clinically significant infections
Occurence of infections that require specific treatment and/or hospitalisation during the study period of 12 months
Time frame: during 12 months
endotoxin levels
Endotoxin in serum (EU/ml)
Time frame: 0, 6, 12 months
neutrophil oxidative burst
percentage of neutrophil granulocytes showing oxidative burst with and without stimulation and mean fluorescence activity
Time frame: 0, 6, 12 months
neutrophil toll like receptor expression
percentage of neutrophil granulocytes showing TLR (Toll-like receptor) 2, TLR4 or TLR9 expression and mean fluorescence activity
Time frame: 0, 6, 12 months
albumin oxidation
oxidative status of albumin in the plasma (percentage of (human mercaptalbumin) HMA, (human non-mercaptalbumin) HNA1 and HNA2)
Time frame: 0, 6, 12 months
inflammatory response
elevation of one or more inflammatory markers: C reactive protein (mg/ml), lipopolysaccharide binding protein (ng/ml), soluble CD (cluster of differentiation) 14 (ng/ml)
Time frame: 0, 6, 12 months
bacterial flora
isolation of bacterial DNA and sequencing the gut microbiome from stool and duodenal aspirate
Time frame: 0, 6, 12 months
quality of life
(short form) SF-36 questionaire
Time frame: 0, 6, 12 months
nutritional status
subjective global assessment
Time frame: 0,6, 12 months
changes in gut permeability over time
elevated lactulose mannitol ratio, elevated zonulin
Time frame: 0, 6, 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.